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Abstract
Objectives: Perioperative factors can affect outcomes of liver transplantation (LT) in recipients with
hepatitis C virus (HCV) infection. This study was conducted to investigate whether the immunomodulatory
effects of packed red blood cells (PRBC) and platelets administered in the perioperative period might
affect immune responses to HCV and thus outcomes in LT recipients.
Methods: Data for a total of 257 HCV LT recipients were analysed. Data on clinical demographics
including perioperative transfusion (during and within the first 24 h), serum cytokine concentration,
HCV-specific interferon-g (IFN-g) and interleukin-17 (IL-17) producing cells, and outcomes including graft
and patient survival were analysed.
Results: Patient survival was higher in HCV LT recipients who did not receive transfusions (Group 1,
n = 65) than in those who did (Group 2, n = 192). One-year patient survival was 95% in Group 1 and 88%
in Group 2 (P = 0.02); 5-year survival was 77% in Group 1 and 66% in Group 2 (P = 0.05). Group 2 had
an increased post-transplant viral load (P = 0.032) and increased incidence of advanced fibrosis at 1 year
(P = 0.04). After LT, Group 2 showed increased IL-10, IL-17, IL-1b and IL-6, and decreased IFN-g, and a
significantly increased rate of IL-17 production against HCV antigen. Increasing donor age (P = 0.02),
PRBC transfusion (P < 0.01) and platelets administration were associated with worse survival.
Conclusions: Transfusion had a negative impact on LT recipients with HCV. The associated early
increase in pro-HCV IL-17 and IL-6, with decreased IFN-g, suggests that transfusion may be associated
with the modulation of HCV-specific responses, increased fibrosis and poor transplant outcomes.
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Introduction
The prevalence of hepatitis C virus (HCV) infection is high: an
estimated 170–200 million people are affected worldwide.1 In the
USA, it is estimated that 3.2 million people are infected with
HCV1,2 and many develop complications of infection, including
liver cirrhosis and failure, and hepatocellular carcinoma (HCC).
These HCV-mediated end-stage liver diseases have become the
leading indication for liver transplantation (LT) in the USA.3,4
Although LT is an available therapeutic option for patients with
chronic HCV, the recurrence of HCV infection in the liver graft is
nearly universal.5 Further, following HCV infection of the allo-
graft liver, the progression of HCV-mediated liver injury and cir-
rhosis is rapid and severe compared with the natural progression
of HCV disease in the native liver. This accelerated progression of
liver fibrosis post-LT is seen in about 10–30% of LT recipients with
HCV infection, and often results in advanced fibrosis and liver
cirrhosis soon after LT.5
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A number of risk factors have been associated with HCV recur-
rence after transplantation, including factors pertaining to the
recipient, donor or the virus itself.6–10 Perioperative inflammation
including inflammation caused by ischaemia–reperfusion injury
has been proposed to facilitate viral persistence and replication.
The replication of HCV and infection of the graft occur soon after
reperfusion and viral loads return to pre-transplant levels within
days after transplant.9
In addition, immunological factors in the recipient can control
the course of HCV replication.4 The present group’s studies have
demonstrated that the development of a T-helper 17 type immune
response against HCV antigens is associated with increased
liver fibrosis.11 By contrast, a viral antigen-specific interferon-g
(IFN-g) response helps to suppress the virus and prevent viral
replication.11,12
In the early days of organ transplantation, a distinct immuno-
suppressive effect was noted when blood products were adminis-
tered prior to transplantation. In canine models, prolonged
kidney graft survival was seen with pre-transplant blood transfu-
sion.13 Further, in 1973, a large study conducted in 148 cadaveric
kidney transplant patients by Opelz et al. demonstrated that
1-year graft survival was significantly better (66% versus 29%) in
patients who received a blood transfusion than in those who did
not and this effect was directly proportional to the number of
units of blood received.14 Similar findings were reported by oth-
ers,15,16 and platelet transfusion was also noted to have a beneficial
effect on allograft outcome.17–19 Although the exact mechanisms
for these immunosuppressive properties were unknown, these
studies led to the conclusion that blood products have immu-
nomodulatory effects.20–23 However, a negative effect clearly
apparent in all of these early studies was an increase in allo-
sensitization in patients with transfusion. The presence of leuko-
cytes was correlated with sensitization.24 Hence, strategies to
deplete blood of the leukocyte fraction using washing, filtration
and other methods were employed.25
Subsequent to the advent of newer and better immunosuppres-
sive drugs, reports have demonstrated that blood transfusion may
actually be detrimental to longterm allograft function.26 Blood
transfusion was also noted to have a negative impact on postop-
erative outcomes in a variety of surgical settings.27–33 Various
studies following lung, intestinal, cardiac, liver and other surgery
demonstrated that an increase in blood transfusion can increase
postoperative complications and the incidence of infections, as
well as the recurrence of cancer.27–33
The effects of blood product administration and trans-
fusion following kidney transplantation have been well
studied.14,15,19,20,26,34–37 Although these findings cannot be directly
translated to LT, various studies have suggested that the transfu-
sion of blood products plays a controversial role in outcome fol-
lowing LT,38–40 particularly in terms of its effect on HCV
recurrence after LT. Hence, in view of the immunomodulatory
properties of blood products, the goal of this study was to deter-
mine the effects of perioperative blood transfusion (blood prod-
ucts administered during or within the first 24 h of transplant) on
transplant outcome in HCV-infected LT recipients. The study
demonstrated that perioperative blood transfusion was associated
with decreased overall survival in HCV LT recipients. Further,
blood transfusion was associated with the modulation of immune
responses to HCV, including the development of Th17 with sup-
pression of the HCV-specific IFN-g response.
Materials and methods
Patient population
All adult LT patients submitted to transplant for HCV-mediated
liver disease between 1 January 2002 and 31 December 2010 at
Barnes Jewish Hospital, Washington University School of Medi-
cine were included in this retrospective study. Infection with HCV
was confirmed by an HCV-positive RNA quantitative polymerase
chain reaction (qPCR) (detection limit of 50 IU/ml; Cobas®
Amplicor; Roche Diagnostics, Indianapolis, IN, USA) and anti-
HCV antibody enzyme-linked immunosorbent assay (ELISA)
(Abbot Laboratories, Chicago, IL, USA). Viral load and genotype
were determined for all patients. Liver transplant patients with
hepatitis B virus (HBV) and/or human immunodeficiency virus
(HIV) co-infection, those with liver disease of other aetiology and
those aged < 18 years were excluded. Demographic and clinical
data were obtained retrospectively from a prospective database on
all LT patients maintained at the study centre. Details of blood
products administered were obtained from patient charts and the
blood bank. Liver transplant recipients with HCV for whom
transfusion details were not available were excluded from the
study. Pre-transplant laboratory parameters, including haemo-
globin, bilirubin, platelet count and transaminases, were deter-
mined just prior to transplant. A pre-transplant laboratory Model
for End-stage Liver Disease (MELD) score was calculated for all LT
recipients. Donor liver quality (including extent of steatosis) was
determined by a liver biopsy obtained from the left lateral segment
either at the time of procurement or after reperfusion.
Blood samples were obtained pre-transplant and at 1 month, 6
months and 1 year post-transplant. Pre-transplant blood was
obtained just before surgery (before any blood products were
administered) and post-transplant blood was obtained during a
scheduled outpatient visit. A protocol liver biopsy was performed
in all patients at approximately 1 year (10–14 months) post-
transplant. Biopsies were graded by pathologists for fibrosis and
necroinflammatory activity using the modified Batts–Ludwig
scoring system,41 which grades for fibrosis stage and inflammatory
grade. Biopsies were categorized into those with advanced fibrosis
(stages 3 and 4) and those without fibrosis (stages 0–2). Patients
for whom biopsy details were not available were excluded from the
study. Informed consent was obtained from all patients and the
study was approved by the institutional review board at Washing-
ton University in St Louis.
At this centre, a standard three-drug immunosuppression
regimen that includes tacrolimus (Prograf; Astellas Pharma US,
Inc., Northbrook, IL, USA), corticosteroids and an antimetabolite
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(most commonly mycophenolate) is used. Methylprednisolone
is administered intraoperatively (1000 mg) and is followed by
oral prednisone, which is tapered over 3–6 months. Biopsy-
confirmed acute rejection is treated with bolus steroids as first-
line therapy and, in rare instances, with thymoglobulin or OKT3
in non-responders.
Blood product and transfusion policy
Blood products transfused included whole blood, packed red
blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitates
and platelets. Transfusion was delivered according to the judge-
ment of the individual physician and based on, but not limited to,
clinical parameters such as blood pressure, cardiac output, blood
loss, coagulopathy and other laboratory findings. If blood prod-
ucts were utilized, they were mostly allogeneic; autotransfusion
with salvaged blood was utilized only rarely.
Isolation of serum and peripheral blood
mononuclear cells
Recipient serum was obtained from whole blood. Peripheral
blood mononuclear cells (PBMC) were isolated by Ficoll-
Hypaque density gradient centrifugation. Following isolation,
cells were used either immediately or were frozen in 10% dimethyl
sulphoxide.
Hepatitis C virus antigens
Recombinant HCV core (Fitzgerald Industries International, Inc.,
Acton, MA, USA), HIV (Gp120 peptide; Biosynthesis, Inc., Lewis-
ville, TX, USA) and phytohaemagglutinin (PHA) (Sigma-Aldrich,
Inc., St Louis, MO, USA) peptide antigens were tested endotoxin-
free by litmus amoebocyte limulus assay (Charles River Labora-
tories, Charleston, SC, USA). Samples of PBMC were stimulated
with 5 mg/ml of each antigen overnight in 24-well plates (Corning,
Inc., Corning, NY, USA) at 37 °C in 5% carbon dioxide (CO2).
Enzyme-linked immunospot assay to determine
HCV-specific immune responses
Enzyme-linked immunospot assay (ELISpot) was carried out as
described previously.11 Stimulated PBMC were cultured in tripli-
cate (3 ¥ 105 cells/200 ml) in immunospot plates (Millipore Corp.,
Billerica, MA, USA) in the presence of antigens (5 mg/ml) for
48–72 h in 5% CO2 at 37 °C. IFN-g (BD Biosciences, Inc., San Jose,
CA, USA) and interleukin-17 (IL-17) (eBioscience, Inc., San
Diego, CA, USA) ELISpot was performed according to the manu-
facturer’s instructions. The plates were washed and spots analysed
in an ImmunoSpot Image Analyzer (Cellular Technology Ltd,
Cleveland, OH, USA). Cells cultured in medium (Cellular Tech-
nology Ltd) and HIV Gp120 peptide were used as negative con-
trols; PHA was used as a positive control. Counted spots were
expressed as spots per million cells (spm).
Multiplex bead Luminex® assay to measure
serum cytokines
Serum cytokines [IL-1b, IL-1ra, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-10, IL-12p40, IL-13, IL-15, IL-17, tumour necrosis
factor-a (TNF-a), IFN-a, IFN-g, granulocyte macrophage
colony-stimulating factor (GM-CSF)] and chemokines (MIP-1c,
MIP-1b, IP-10, MIG, eotaxin, RANTES, MCP-1) were measured
using multiplex bead immunoassays (Invitrogen, Inc., Carlsbad,
CA, USA) performed as per the manufacturer’s instructions. The
Luminex xMAP™ system was used to read plates and to determine
the mean fluorescence intensity (MFI) of experimental and stand-
ard wells. Cytokine and chemokine concentrations were obtained
using a standard curve and expressed in pg/ml.
Statistical analysis
Analysis was performed using GraphPad Prism Version 5.0b
(GraphPad Software, Inc., La Jolla, CA, USA) and IBM spss Statis-
tics Version 21.0 (IBM Corp., Armonk, NY, USA). Data were
checked for normality using the Shapiro–Wilk test and non-normal
data were log-transformed. Clinical demographics and immuno-
logical parameters were compared using the Kruskal–Wallis test,
chi-squared test and analysis of variance (anova) as appropriate.
Kaplan–Meier survival curves and the log-rank test were used for
allograft and patient survival analyses. A univariate logistic regres-
sion analysis stratified by log rank was performed to determine
factors associated with patient and graft survival. Variables with a
possible association (P < 0.10) were selected for a second multivari-
ate regression model. These selected variables were analysed using
Cox proportional hazard regression with forward stepwise selection
to identify variables independently associated with poor graft and
patient survival. A two-sided level of significance was set at P < 0.05.
Results
Patient demographics
A total of 702 LTs were performed between 1 January 2002 and 31
December 2010 at the study centre.Amongst these, 280 transplants
were performed in adult HCV patients and were eligible to be
included for analysis. Detailed demographic, transfusion and clini-
cal data, with at least 1 year of follow-up, were available for 257
patients (74 women, 183 men). Perioperative transfusion was
defined as any transfusion during LT surgery or within 24 h of LT.
Patients were classified into two groups: Group 1 included patients
who did not receive any perioperative transfusion of any blood
product (n = 65), and Group 2 included patients who were
transfused perioperatively with at least one unit of whole blood/
PRBC/FFP/cryoprecipitate or platelets (n = 192). The clinical
demographics of both groups are described in Table 1. Those who
were transfused were younger (median age: 52 years). Fifty (76.9%)
patients in Group 1 and 64 (33.3%) in Group 2 had HCC along
with HCV (P= 0.001). In general, patients who were transfused had
a higher pre-transplant MELD score, higher bilirubin, higher inter-
national normalized ratio (INR) and lower haemoglobin (Table 1).
There were no differences in warm or cold ischaemia times or the
degree of ischaemia–reperfusion injury. Donor liver quality was
similar in both groups, as was the utilization of liver grafts donated
after cardiac death. There was no difference in pre-transplant HCV
viral load or genotype; HCV genotype 1a infection was the most
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prevalent in the study cohort. There was no difference in donor and
recipient cytomegalovirus (CMV) status.
Transfusion characteristics of HCV LT recipients
Among the 192 HCV LT recipients who were transfused, 20
(10.4%) patients received whole blood in the perioperative
period. PRBC were administered to 180 (93.8%) patients. Fresh
frozen plasma was utilized in 163 (84.8%) patients and platelets in
72 (37.5%) patients. Cryoprecipitates were mostly administered
during transplant and were utilized in 95 (49.5%) patients. A total
of 72 (37.5%) patients received all three of FFP, platelets and
PRBC. Data on the number of units of blood products (i.e. whole
Table 1 Clinical demographics of hepatitis C virus (HCV)-infected liver transplant (LT) recipients who did and did not receive perioperative
(during LT and within the first 24 h post-LT) blood product transfusions
Demographic characteristic Group 1, non-transfused
(n = 65)
Group 2, transfused
(n = 192)
P-value
Recipient age at LT, years, median (range) 55 (45–74) 52 (27–75) 0.009
Recipient gender, n (%) 0.554
Female 14 (21.5%) 60 (31.3%)
Male 51 (78.5%) 132 (68.8%)
Recipient race, n (%) 0.332
White 53 (81.5%) 156 (81.3%)
African-American 11 (16.9%) 24 (12.5%)
Other 1 (1.5%) 12 (6.2%)
Hepatocellular carcinoma, n (%) 50 (76.9%) 64 (33.3%) 0.001
Retransplant, n (%) 0 8 (4.2%) 0.063
Donor age, years, median (range) 47 (10–76) 42 (10–76) 0.028
Donor race, n (%) 0.582
White 54 (85.7%) 145 (75.5%)
African-American 6 (9.5%) 31 (16.1%)
Other/unknown 5 (7.8%) 16 (8.4%)
Donor (D)/recipient (R) CMV status, n (%)
D-/R- 10 (15.3%) 33 (17.2%) 0.133
D+/R- 16 (24.6%) 39 (20.3%)
D-/R+ 17 (26.2%) 23 (12.0%)
D+/R+ 12 (18.4%) 60 (31.2%)
N/A 10 (15.3%) 37 (19.2%)
Pre-LT bilirubin, mg/dl, median (range) 2.68 (2–6) 7.08 (3–58) <0.001
Pre-LT INR, median (range) 1.31 (1.00–3.00) 1.95 (1.02–5.06) <0.001
Pre-LT Hb, mg/dl, median (range) 13.2 (8–16) 10.9 (7–17) <0.001
Pre-LT platelet count, in 105, median (range) 88.6 (30–351) 84.1 (10–330) 0.493
Pre-LT MELD score, median (range) 12 (6–24) 21 (7–51) <0.001
Pre-LT creatinine, mg/dl, median (range) 1.1 (0.6–4) 1.2 (0.3–8) 0.435
Pre-LT HCV viral load, 106 copies/ml, median (range) 0.42 (0.1–1.01) 0.31 (0.3–1.14) 0.334
Post-LT HCV viral load, 106 copies/ml, median (range) 5.6 (0.6–10.1) 10.3 (0.3–15.4) 0.032
HCV genotype, n (%) 1–14 (21.5%) 1–30 (15.6%) 0.275
1a: 20 (30.8%) 1a: 72 (38%)
1b: 10 (15.4%) 1b: 40 (20.8%)
2a: 3 (4.7%) 3: 6 (3.1%)
N/A: 18 (27.6%) N/A: 44 (22.9%)
Cold ischaemia time, min, median (range) 345.5 (85–748) 370.4 (79–878) 0.251
Warm ischaemia time, min, median (range) 35.8 (20–80) 34.9 (15–69) 0.513
N/A, not available; CMV, cytomegalovirus; INR, international normalized ratio; Hb, haemoglobin; MELD, Model for End-stage Liver Disease.
P-values in bold indicate statistically significant differences (P < 0.05).
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blood, PRBC, FFP, cryoprecipitate, platelets) and time of admin-
istration are described in Table 2.
Pre-transplant bilirubin, MELD score and
haemoglobin are predictive of PRBC transfusion in
HCV LT recipients
To determine variables predictive of PRBC administration in the
perioperative period, odds ratios (ORs) were calculated. As
Table 3 shows, high pre-transplant bilirubin [(OR) = 1.52, 95%
confidence interval (CI) 0.023–2.253; P = 0.037] and a high MELD
score (OR = 1.173, 95% CI 1.032–1.333; P = 0.015) were predictive
of PRBC transfusion. Haemoglobin (OR = 0.662, 95% CI 0.521–
0.842; P = 0.001) was also predictive of PRBC transfusion [i.e. the
lower the haemoglobin, the greater the likelihood of transfusion
(as noted by an OR of < 1)]. Other variables, including platelet
count, creatinine and donor age, were not predictive of PRBC
transfusion (Table 3).
Increased postoperative intensive care unit and
hospital stay in transfused patients
All LT recipients were taken to the intensive care unit (ICU) post-
operatively for at least 1 day; the decision to transfer a patient out
of the ICU varied according to the clinical situation. The duration
of ICU stay was calculated as the number of postoperative days
spent in the ICU, and the duration of hospital stay as the number
of days post-transplant spent in the hospital. As shown in Fig. 1,
HCV LT recipients who were transfused spent more time in both
the ICU and the hospital post-transplant than those who were not
transfused. Amongst the patients who were not transfused, most
went home within 6 days of transplant, whereas those who were
transfused remained in hospital for an average of 13 days.
Increased post-transplant HCV recurrence and
increased incidence of advanced liver fibrosis 1 year
post-transplant in transfused HCV LT recipients
In all patients, HCV viral load was determined by qPCR (Cobas®
Amplicor; Roche Diagnostics). HCV viral load is known to drop
immediately after transplant and to increase soon afterwards.9 To
account for these changes, HCV viral load was determined pre-
transplant and at 3 months post-transplant (range: 2–6 months in
both groups). As Table 1 shows, post-transplant HCV viral load
was 10–40-fold higher than pre-transplant load in all patients.
Post-transplant viral load was significantly higher in LT recipients
who received perioperative blood transfusions than in the non-
transfused cohort, although pre-transplant levels had been similar
Table 2 Blood product utilization during and 24 h after liver transplantation (LT) in hepatitis C virus (HCV)-infected recipients
Blood product Group 1, non-transfused
(n = 65)
Group 2, transfused
(n = 192)
P-value
Whole blood, units, median (range) 0 1 (0–4) 0.04
PRBC during LT, units, median (range) 0 3 (0–102) <0.001
PRBC within 24 h of LT, units, median (range) 0 2 (0–28) <0.001
FFP during LT, units, median (range) 0 5 (0–70) <0.001
FFP within 24 h of LT, units, median (range) 0 1 (0–21) 0.008
Cryoprecipitate during LT, units, median (range) 0 1 (0–10) <0.001
Cryoprecipitate within 24 h of LT, units, median (range) 0 1 (0–2) 0.037
Platelets during LT, units, median (range) 0 1 (0–12) 0.001
Platelets within 24 h of LT, units, median (range) 0 1 (0–5) 0.002
PRBC, packed red blood cells; FFP, fresh frozen plasma.
Table 3 Regression analysis to determine predictors of peri-liver
transplant (LT) packed red blood cell transfusion requirement
Variable Odds ratio (95% CI) P-value
Recipient age 1.023 (0.957–1.093) 0.507
Donor age 0.995 (0.971–1.019) 0.685
Pre-LT bilirubin 1.52 (1.025–2.253) 0.037
Pre-LT INR 0.688 (0.254–1.865) 0.462
Pre-LT MELD score 1.173 (1.032–1.333) 0.015
Pre-LT haemoglobin 0.662 (0.521–0.842) 0.001
Pre-LT creatinine 1.033 (0.887–1.334) 0.559
Pre-LT platelet count 1.008 (1–1.016) 0.056
Cold ischaemia time 1.002 (0.999–1.005) 0.115
95% CI, 95% confidence interval; INR, international normalized ratio;
MELD, Model for End-stage Liver Disease.
P-values in bold indicate statistical significance (P < 0.05).
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Figure 1 Median duration of intensive care unit (ICU) and hospital
stay in liver transplant patients with hepatitis C virus infection who
did and did not receive perioperative transfusion with any blood
product
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between the groups (P = 0.032). Further, the change in HCV viral
load (from pre- to post-transplant) was significantly greater in
transfused than in non-transfused patients [mean  standard
error (SE) fold change: 35.2  3.4 in Group 2 and 11.4  5.6 in
Group 1; P = 0.001]. This suggests a possible relationship between
blood transfusion and increased HCV replication.
Additionally, all HCV LT recipients underwent a 1-year proto-
col liver biopsy post-LT to determine the status of HCV infection
in the liver. Pathologists scored liver biopsies for fibrosis stage and
inflammatory activity using the modified Batts–Ludwig scoring
system.41 All patients demonstrated some changes as a result of
HCV re-infection of the graft. Among the 180 patients who had
received PRBC transfusions, 66 (36.7%) had advanced fibrosis
(Batts–Ludwig stage 3–4), whereas only 14 (18.2%) of the 77
patients who did not receive PRBC did so (P = 0.04). There were
no differences in the groups of patients to whom FFP, cryopre-
cipitates or platelets were administered in the incidence of
advanced fibrosis (data not shown).
Effect on acute rejection following LT
Biopsy-confirmed acute rejection episodes in the first year post-
transplant were present in 21 patients in the entire cohort. Most of
these rejection episodes occurred within the first month after
transplantation. In the group to whom PRBC were administered,
5.7% of patients had at least one episode of acute rejection,
whereas 15.3% of patients in the non-transfused group did so.
However, this difference was not statistically significant (P =
0.061). It has been suggested that a ‘small’ number of units of
blood may actually have a protective effect on the graft.26 Hence,
incidences of acute rejection were compared among patients who
received 1–3 units of PRBC, patients who did not receive any
transfusions, and patients who received > 3 units of PRBC. Of the
52 patients who received 1–3 units of blood, only one (1.9%)
patient experienced acute rejection, whereas 12.3% of patients
who received > 3 units and 15.3% of non-transfused patients
experienced acute rejection (P = 0.001). The distinction between
rejection and HCV recurrence in liver biopsy can be difficult to
make; however, the decision to treat rejection at the study centre
depends on close discussion among the centre’s pathologists. In
the present patient population, the distinction between rejection
and recurrence could not be established in six patients (including
two who received > 3 units of blood and four non-transfused
patients), but all of these patients were treated for rejection and
demonstrated clinical improvement as indicated by reductions in
transaminases and other parameters.
Incidence of other complications
Postoperative bleeding during the first week after transplantation
was noted to be higher in the transfused (15.3%) than in the
non-transfused (9.3%) cohort (P = 0.04). However, it is possible
that this reflects the increased transfusion needs post-LT of coagu-
lopathic patients who have already received perioperative trans-
fusions. None of the patients in the non-transfused cohort
received any transfusions in the later postoperative period. Of the
192 patients who were transfused perioperatively, 153 (79.7%) did
not receive further transfusions. The remaining 39 (20.3%)
patients received transfusions (range: 1–8 units) within the first
week of transplant.
Incidences of other surgical complications, including vascular
and biliary complications, were similar in both groups. Donor (D)
and recipient (R) CMV status was similar in both groups and
CMV reactivation among the 214 patients at risk (D+/R- or
D-/R+ or D+/R+) occurred in 5.4% of patients in the non-
transfused cohort and 11.3% in the transfused cohort in the first
year after transplantation (P = 0.06).
Antiviral therapy for HCV at this institution consists of IFN-a
and ribavirin. None of the patients had a sustained virological
response (SVR) to treatment prior to transplant and all trans-
planted patients had a detectable viral load prior to transplant. In
general, most patients are not offered antiviral therapy within the
first year of transplant; however, in some instances of clinical wors-
ening of liver disease without evidence of rejection and with an
increasing viral load, specific antiviral therapy is initiated. Further
continuation of therapy depends on tolerance and treatment
response. In the first year after LT, five (7.7%) patients in the non-
transfused cohort and 28 (14.6%) patients in the transfused cohort
received antiviral therapy. Of these, 33.3% failed to complete
therapy as a result of significant side-effects. Incidences of SVR in
the patients who completed therapy were similar in both groups
(approximately 30%). None of the patients analysed in the current
study received the newer protease inhibitors as antiviral therapy.
Increased serum IL-17, IL-1b, IL-6, IL-4, IL-5, IL-10
cytokines and suppression of IFN-g in transfused HCV
LT patients
To determine the serum concentrations of cytokines and chem-
okines pre-transplant and at 1 month, 6 months and 1 year post-
LT, serum was analysed by 25-plex Luminex®. In order to
eliminate any potential confounding factors, only patients who
had received perioperative transfusions and no further transfu-
sions in the postoperative period were included. Patients who
received antiviral therapy (pre- or post-transplant), had HCC, had
rejection episodes, had CMV reactivation or any other illness
(respiratory infection, diarrhoea, etc.) 1 month before or after
sample collection were also excluded. According to these criteria
and the availability of serial samples, only 30 (46.2%) patients in
the non-transfused cohort and 85 (44.3%) in the transfused
cohort were included for analysis. The demographics and clinical
profiles of these groups of LT recipients did not differ from those
of the entire non-transfused and transfused cohorts, respectively
(data not shown). As Table 4 shows, there were no differences in
the pre-transplant cytokine profiles of these patient groups.
However, patients who were transfused had significantly higher
serum concentrations of IL-17, IL-1b, IL-6, IL-4, IL-5 and IL-10 as
early as 1 month post-transplant. These levels continued to be
higher in the transfused cohort at 6 months and at 1 year post-LT.
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Similarly, concentrations of IFN-g in patients who were transfused
were significantly lower than those in patients who were not trans-
fused. This demonstrates that patients who were transfused had
an associated increase in IL-17 and pro-Th17 (IL-6, IL-1b) and
Th2 cytokines (IL-4, IL-10, IL-5) and decreased Th1 cytokine
(IFN-g). Concentrations of other cytokines and chemokines did
not vary among the groups (data not shown).
Transfused HCV LT patients have an increased
frequency of HCV-specific IL-17 and decreased
frequency of IFN-g secreting cells 1 year post-LT
In order to determine the cellular responses specific to HCV,
PBMC from transfused and non-transfused patients, respectively,
were stimulated with HCV core antigen and cells secreting IL-17
or IFN-g were enumerated by ELISpot. As Fig. 2 shows, patients
who were transfused in the perioperative period had an associated
increase in HCV core-specific IL-17 producing cells compared
with non-transfused patients (P = 0.003). However, there was a
significant suppression of HCV-specific IFN-g producing cells in
patients who were transfused (P = 0.002).
HCV LT patients administered with PRBC or platelets
have decreased patient and graft survival rates
Patient and graft survival were analysed using Kaplan–Meier sur-
vival curves and log-rank tests. A comparison of transfused and
non-transfused patients showed survival to be significantly lower
in the transfused group (n = 192) at 1 year (88% versus 95%; P =
0.02) and at 5 years (66% versus 77%; P = 0.05). In particular, as
Fig. 3(a, b) shows, LT patients who received PRBC had signifi-
cantly decreased 1-year and 5-year patient and graft survival com-
pared with those who did not. Similarly, HCV LT recipients who
received platelets had significantly lower survival than those who
did not (Fig. 3c, d) at both 1 year and 5 years.
Patients transfused with PRBC were further stratified into sub-
groups of patients who received, respectively, 1–3 units, 4–6 units
or 7 units of blood. As Fig. 4 shows, patients who received  7
Table 4 Serum cytokine concentration measured by 25-plex Luminex® pre-liver transplantation (LT), 1 month post-LT, 6 months post-LT and
1 year post-LT in hepatitis C virus (HCV)-infected patients who were or were not perioperatively transfused
Cytokine Pre-LT 1 month post-LT 6 months post-LT 1 year post-LT
Group 1,
non-
transfused
Group 2,
transfused
P-value Group 1,
non-
transfused
Group 2,
transfused
P-value Group 1,
non-
transfused
Group 2,
transfused
P-value Group 1,
non-
transfused
Group 2,
transfused
P-value
IL-17, pg/ml 64.3  11.2 70.2  20.2 0.10 13.4  8.71 44.1  11.5 0.03 24.5  15.6 88.9  20.1 0.014 33.3  5.5 100.3  22.2 0.011
IL-1b, pg/ml 45.4  16.1 40.5  15.3 0.22 10.2  7.33 40.4  7.9 0.01 34.5  9.3 70.5  6.5 0.00 29.4  11.1 88.3  18.5 0.002
IL-6, pg/ml 50.4  14.9 60.1  21.5 0.54 12.1  6.21 64.3  11.3 0.01 27.5  13.8 80.1  20.1 0.009 30.3  9.9 94.4  25.3 0.005
IL-4, pg/ml 70.1  17.3 79.5  16.4 0.44 43.2  10.5 98.5  20.1 0.02 39.3  8.1 120.3  17.9 0.003 44.8  13.9 111.3  12.2 0.002
IL-5, pg/ml 55.6  20.2 70.9  28.4 0.21 15.3  4.4 52.2  11.6 0.02 50.6  20.3 89.4  18.9 0.010 55.5  25.2 100.3  21.7 0.020
IL-10, pg/ml 47.9  11.4 54.3  17.7 0.69 13.3  6.5 39.2  10.1 0.03 40.5  4.9 68.8  5.7 0.040 44.5  18.3 74.3  19.2 0.010
IFN-g, pg/ml 20.4  5.6 19.9  6.1 0.8 95.3  17.7 45.6  18.9 0.01 124.9  29.4 30.1  10.3 0.001 100.9  8.0 23.1  11.2 0.001
TGF-b, pg/ml 145.7  21.9 120.3  24.3 0.32 24.5  3.7 60.5  11.9 0.009 40.5  18.9 166.4  31.4 0.002 50.3  23.4 188.9  31.5 0.005
IL, interleukin; IFN, interferon; TGF, transforming growth factor.
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Figure 2 Increased hepatitis C virus (HCV)-specific interleukin-17 (IL-17) and decreased interferon-g (IFN-g) secretion in HCV-infected liver
transplant patients who received perioperative blood transfusions, determined by enzyme-linked immunospot (ELISpot) comparing IL-17
and IFN-g responses to HCV core antigen. Peripheral blood mononuclear cells (PBMC) at 3 ¥ 105 per well were stimulated with HCV core
antigen of human immunodeficiency virus (HIV) Gp120 peptide (negative control) or PHA (positive control) at 5 mg/ml concentration, and
IL-17 and IFN-g spots enumerated. Data are presented as the mean  standard error number of spots per million cells and compared using
the Mann–Whitney U-test
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Figure 3 Kaplan–Meier survival curves depicting overall patient and graft survival in hepatitis C virus (HCV)-infected liver transplant patients
who were or were not perioperatively transfused with (a, b) packed red blood cells (PRBC) or (c, d) platelets
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units of blood had the lowest 1- and 5-year patient survival of all
the groups. There was no effect of FFP, cryoprecipitate or whole
blood transfusion on overall transplant outcomes.
Multivariate regression analysis demonstrates that
donor age and transfusion of platelets or PRBC
are independent predictors of post-LT survival in
HCV LT patients
To determine variables affecting post-LT survival, a univariate
regression analysis was performed. All factors that were found to
differ significantly between the cohorts (Table 1) were included in
the univariate regression model. Donor age, pre-transplant plate-
let count, warm ischaemia time, transfusion of platelets, FFP or
PRBC caused a higher hazard to patient survival (P < 0.1)
(Table 5). Variables such as MELD score and bilirubin level were
not associated with patient survival. These variables were then
selected and analysed in a multivariate Cox regression model. As
Table 6 shows, donor age [hazard ratio (HR) = 1.019, 95% CI
1.004–1.034; P = 0.003], transfusion of platelets (HR = 1.069, 95%
CI 1.008–1.134; P = 0.026) and PRBC transfusion (HR = 1.364,
95% CI 1.116–1.666; P = 0.002) were independently associated
with poor patient survival. The P-value for the constructed Cox
model comparing survival differences between the transfused and
non-transfused cohorts was < 0.0001.
Discussion
Blood transfusion is commonly used in LT recipients and critically
ill patients to increase the oxygen-carrying capacity of blood and
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Figure 4 Kaplan–Meier survival curves for hepatitis C virus (HCV)-
infected liver transplant patients stratified by number of periopera-
tive units of packed red blood cells (PRBC) transfused. Group 1: 0
units; Group 2: 1–3 units; Group 3: 4–6 units; Group 4:  7 units
Table 5 Univariate regression analysis of variables affecting overall
survival after liver transplantation (LT) in hepatitis C virus (HCV)-
infected patients. Variables associated with mortality (P < 0.1) were
utilized to construct a multivariate Cox regression model (Table 6)
Variable HR (95% CI) P-value
Recipient age 0.982 (0.947–1.018) 0.323
Recipient race (African-American) 3.09 (0.334–4.537) 0.633
Recipient sex (male) 1.04 (0.507–1.579) 0.834
Donor age 1.019 (1.004–1.034) 0.011
Donor sex (male) 1.003 (0.956–1.225) 0.524
Pre-LT PT/INR 0.972 (0.706–1.337) 0.861
Pre-LT MELD score 1.012 (0.985–1.039) 0.4
Pre-LT serum bilirubin 0.996 (0.964–1.029) 0.825
Pre-LT haemoglobin 1.006 (0.901–1.123) 0.919
Pre-LT platelet count 1.004 (1.000–1.008) 0.067
Cold ischaemia time 0.999 (0.997–1.001) 0.213
Warm ischaemia time 0.968 (0.935–1.002) 0.067
Perioperative platelet transfusion 1.049 (1.03–1.068) <0.01
Perioperative FFP transfusion 1.065 (1.036–1.094) <0.01
Perioperative cryoprecipitate
transfusion
1.089 (0.940–1.262) 0.254
Perioperative PRBC transfusion 1.339 (1.182–1.518) <0.01
Rejection 1.003 (0.879–1.122) 0.774
Complications 1.045 (0.344–4.557) 0.559
HR, hazard ratio; 95% CI, 95% confidence interval; PT, prothrombin time;
INR, international normalized ratio; MELD, Model for End-stage Liver
Disease; FFP, fresh frozen plasma; PRBC, packed red blood cells.
Values in bold indicate statistical significance (P < 0.05).
Table 6 Multivariate Cox proportional hazard model determining
variables that are independently associated with post-transplant
mortality in hepatitis C virus (HCV)-infected liver transplant patients
Variable Adjusted HR (95% CI) P-value
Donor age 1.019 (1.004–1.034) 0.003
Pre-LT platelet count 1.005 (0.993–1.010) 0.067
Warm ischaemia time 0.965 (0.930–1.002) 0.061
Perioperative platelet transfusion 1.069 (1.008–1.134) 0.026
Perioperative FFP transfusion 1.080 (0.930–1.254) 0.314
Perioperative PRBC transfusion 1.364 (1.116–1.666) 0.002
HR, hazard ratio; 95% CI, 95% confidence interval; FFP, fresh frozen
plasma; PRBC, packed red blood cells.
Values in bold indicate statistical significance (P < 0.05).
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for volume replacement. Fresh frozen plasma, platelets and cryo-
precipitates also help to correct coagulopathies.42 However, their
utilization is associated with risk for transfusion reactions
ranging from hypersensitivity and serum sickness to anaphylaxis
and transfusion-associated lung injury. Currently, it is not clear
whether blood transfusion during the perioperative period affects
longterm outcomes in LT recipients, especially patients with
HCV. This is of relevance because other peri-transplant factors,
including ischaemia–reperfusion injury, have been associated
with the worsening of HCV recurrence following LT.9 This study
evaluated the role of perioperative blood product administration
in overall transplant outcome, as well as HCV-specific immune
responses in HCV LT recipients. These findings agree with those
published by others demonstrating a significant effect of PRBC
and platelet transfusion on survival in LT patients.38,39 Ramos
et al. demonstrated that transfusion of > 6 units of PRBC was not
only associated with poor survival, but also resulted in an
increased hospital stay (OR = 3.06; P = 0.032).39 Similarly, in the
present study, transfusion was associated with increased ICU and
hospital stay, as well as with poor post-transplant survival, espe-
cially in patients receiving  7 units of blood products. Nacoti
et al.43 found PRBC transfusion to be significantly associated with
poor 1-year survival in a cohort of 243 paediatric LT patients (HR
= 3.15; P = 0.033) and confirmed this finding with an independ-
ent risk-adjusted analysis similar to the multivariate regression
model used in the present study. Although it can be argued that
sicker patients do worse, have an increased hospital stay and
transfusion requirement and hence a poorer outcome, the mul-
tivariate regression and the propensity score-adjusted models
were used to account for such differences. As Tables 5 and 6 show,
PRBC remains an independent predictor of poor outcome even
when variables such as a high MELD score, which are reflective of
degree of sickness or coagulopathy in LT recipients, are accounted
for.
Historically, in animal models of transplantation, preoperative
blood transfusions were described as significantly improving graft
outcome.13,19 This was also noted in clinical renal transplantation,
especially in large studies by Opelz et al. of cadaveric kidney trans-
plants, and in many other independent reports.14–16,34,37 It was
hypothesized that blood products result in immunosuppression
and that leukocytes expressing major histocompatibility complex
(MHC) antigens partly mediate this effect.36,44 Terasaki postulated
that the beneficial effect of transfusion is attributable to clonal
deletion.45 This was particularly relevant in instances of peri- and
postoperative transfusion. According to this theory, transplanta-
tion resulted in an immune response affecting memory cells that
led to the activation of clones directed towards the graft. Blood
transfusion was thought to counteract this by hyperimmunizing
the patient to multiple antigens, and engaging and inactivating
memory responses, and protecting the graft.
However, a major concern in the use of random transfusion was
that patients receiving transfusions had a higher predisposition to
develop antibodies against human leukocyte antigen (anti-HLA)
and thereby become sensitized against potential donors (although
this was more relevant in kidney transplantation).14 This sensiti-
zation occurred as a result of HLA class I and II expressed on
leukocytes in transfused blood46 and, therefore, leukocyte-
depleting strategies were employed to prevent allo-sensitization.
Although these data are not conclusive, this immunosuppres-
sive benefit of blood transfusion was seen in part in the present
study, in which HCV LT recipients who received 1–2 units of
blood seemed to have a reduced incidence of acute rejection.
However, the overall incidence of acute rejection in patients who
received > 2 units of blood was similar to that in the non-
transfused LT patient cohort. Further, there was no distinct sur-
vival benefit conferred by the receipt of < 2 units of blood (Fig. 4).
Hence, because of the small number of patients included in the
present sample, it was difficult to conclude a definite correlation
between acute rejection and transfusion.
Sensitization to HLA can occur following transfusion, which is
relevant in kidney transplantation. However, recent prospective
research from the Mayo Clinic, by Taner et al., demonstrated that
donor-specific antibodies (DSA) against donor HLA may not have
important clinical impact following LT and that even patients
with pre-LT DSA clear it soon after transplant.47 In this centre,
pre- and post-transplant detection of sensitization to donor HLA
is not routinely performed in LT recipients and liver donors are
not usually typed for HLA; hence, this study was unable to evalu-
ate rates of allo-sensitization in the present patient cohorts, espe-
cially after transfusion. This may represent an important avenue
of research in future studies.
It is important to note that most of the studies demonstrating
beneficial effects of blood transfusion on allograft outcome were
carried out before the use of cyclosporine became prevalent.
Studies in the late 1980s and 1990s demonstrated that this appar-
ent effect of blood transfusion may not necessarily be useful.48,49
Lundgren et al. reported no demonstrable difference in patient or
graft survival among patients who were or were not transfused
among 928 kidney transplant recipients receiving calcineurin
inhibitor-based immunosuppression.48 Additional reports estab-
lished a detrimental effect of blood transfusion on longterm graft
function and patient outcomes.35,49 Hence, this concept was largely
abandoned as newer and better immunosuppressive drugs
became available.
Although most of these studies investigating blood transfusion
and transplant outcomes were conducted in the field of kidney
transplantation, studies in liver transplantation in both the adult
and paediatric settings have demonstrated that PRBC and platelet
administration can have significant deleterious effects on trans-
plant outcome.38,39,43 Further, higher incidences of postoperative
infection in transfused patients have been reported in a variety of
surgical settings.27,28,33,42,50 Intraoperative transfusion has also been
associated with an increase in the incidence of cancer recurrence
in colon cancer patients.50 In the present series, although the non-
transfused cohort included more patients with HCC attributable
to HCV, incidences of recurrent HCC were similar in both groups
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(approximately 2%). Similarly, there were no differences in post-
operative infection/complication rates, including the reactivation
of viral infections such as CMV.
Several laboratories have reported that transfusion can exert
immunomodulatory effects. Blood products directly inhibit cel-
lular responses by suppressing antigen presentation and natural
killer cell activity.51,52 More importantly, both in vitro and in vivo
studies have demonstrated that allogeneic blood product admin-
istration can alter the cytokine milieu and mediate a switch of Th1
(producing IFN-g) cells to Th2 (producing IL-10, IL-4 and IL-5)
cells.53,54 These effects have important implications in relation to
HCV-specific immune responses. Natural killer cells are an
important first line of host defence, especially in the early period
of HCV infection.55 Infection of the new graft liver with HCV
occurs soon after reperfusion9 and thus perioperative transfusion
may affect early innate immune responses directed towards HCV.
In addition, the current study found that patients who were trans-
fused showed suppressed Th1 responses in association with a
decrease in serum IFN-g. It is important to note that there was no
difference in the immunological profiles of these patients pre-
transplant. However, post-transplant, even as early as 1 month, a
significant difference in the cytokine profiles of the transfused and
non-transfused cohorts emerged. This effect was apparent after
any potential confounders, such as presence of HCC, rejection
episodes, infections, antiviral therapy and further transfusions,
were eliminated.
Transfused patients also had significantly higher serum levels of
IL-6, IL-1b and transforming growth factor-b (TGF-b). These
cytokines favour the differentiation of Th17 cells.11 This may also
explain the significantly higher HCV-specific IL-17 response at 1
year post-LT (Fig. 2). Early events in the post-LT period are
known to affect the longterm post-LT course of HCV infection.7
Because the changes in serum cytokines were noted in the period
soon after transplant (Table 4), it is possible that these early effects
on the immune response can skew the immunological milieu to
favour HCV replication as seen in the significant increase in viral
load post-transplant, especially in the transfused cohort. In
addition, most patients received transfusions either during or
immediately after transplantation. None of the patients in the
non-transfused cohort received any transfusions in the later post-
operative period, especially when the cytokine profile of HCV
viral load was assessed. Although some patients were transfused in
the first week post-transplant, these additional transfusions in a
small number of patients did not affect overall results in the
present study.
Investigations conducted in the study centre laboratory have
indicated that the increase in IL-17 and suppression of IFN-g,
particularly to HCV antigens, favours the progression of HCV
associated with the development of liver fibrosis post-
transplantation.11 Hence, the increase in proinflammatory
cytokines (IL-17, TGF-b, IL-4, etc.) following transfusion may
favour persistent replication of the virus that may lead to liver
injury and the development of fibrosis. By contrast with those of
Rice et al.,40 the present findings indicate that blood transfusion is
associated with increased HCV recurrence and advanced liver
fibrosis. The recurrence of HCV itself post-transplant is univer-
sal,56 but incidences of progression of advanced liver fibrosis
within 1 year of transplant vary and can reach 30–40% post-
LT.5,56,57 These are similar to the rates observed in the present study
and reflect a variety of factors, including the viral genotype,
immunosuppression and the immunological milieu.5,11,56 The
current study determined an association of blood transfusion
with worsened HCV recurrence, which may be partly explained by
the upregulation of IL-17 seen in these patients.
Given the present findings, it would appear that transfusion
practices in HCV LT recipients should be judicious and unneces-
sary transfusion should be avoided as much as possible. Factors
such as a high MELD score, low haemoglobin and evidence of
coagulopathy (Table 3) are predictive of blood product require-
ment during transplant. In such patients, strategies such as
pre-transplant nutritional build-up to raise iron stores and hae-
matocrit, the use of erythropoietin, the minimizing of intraopera-
tive blood loss and the use of autotransfusion methods may be
considered to avoid the deleterious effects of allogeneic blood
transfusion.
The limitations of this study include its retrospective nature.
The effect of pre-LT transfusion on outcomes could not be
determined as a result of insufficient data. Comorbid conditions,
including diabetes, hypertension and CMV infection, and the
use of antiviral therapy, were accounted for in the multivariate
analysis. Blood samples and biopsy tissue were not available uni-
versally at different time-points, and thus immunological analy-
sis was not performed in all patients. Additionally, as there are
no widely accepted and standardized guidelines for transfusion
policy in LT, differences attributable to the clinical judgements of
the various clinicians involved in the decision for transfusion
(anaesthesiologists, critical care physicians and surgeons) could
not be included in the analysis. This study established clear asso-
ciations of PRBC and platelet transfusion with transplant
outcome, but did not show any effect of FFP, cryoprecipitate or
whole blood transfusion. Nacoti et al. demonstrated that FFP
transfusion in paediatric LT patients was associated with worse
survival.43 The effect of whole blood was not apparent in the
present study because its usage was relatively low (10% of
patients).
In summary, this study demonstrates that blood product
administration in the perioperative period is associated with a
worsened outcome in HCV LT recipients. Perioperative transfu-
sion may be associated with an early modulation of immune
responses that sets up an inflammatory milieu leading to a sup-
pression of HCV-specific IFN-g and activation of IL-17. These
early changes may alter the progression of HCV in the allograft
and may lead to advanced fibrosis, as well as a poor outcome
following LT in HCV recipients. Hence, perioperative transfusion
in HCV LT recipients should be judiciously utilized to improve
longterm outcomes in HCV LT patients.
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